Evidence map›Paper›PMID 30572803›Full record

ArticleStem cells and development2019

Remodeling of Glycosaminoglycans During Differentiation of Adult Human Bone Mesenchymal Stromal Cells Toward Hepatocytes.

Paiyz E Mikael, Charles Willard, Aurvan Koyee, Charmaine-Grace Barlao, Xinyue Liu, Xiaorui Han, Yilan Ouyang, Ke Xia, Robert J Linhardt, Jonathan S Dordick

Abstract read
In one paragraph

Article in Stem cells and development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Influencing factors and mechanism of hepatocyte regeneration.Journal of translational medicine · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paiyz E Mikael1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Charles Willard2 Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York.
Aurvan Koyee3 Department of Biology, University of Virginia, Charlottesville, Virginia.
Charmaine-Grace Barlao4 Department of Biochemistry and Biophysics, Rensselaer Polytechnic Institute, Troy, New York.
Xinyue Liu1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Xiaorui Han1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Yilan Ouyang1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Ke Xia1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Robert J Linhardt1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.
Jonathan S Dordick1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York.

Funding

High-Throughput Platform for Identifying Stem Cell ToxicityR01ES020903 · NIEHS · RENSSELAER POLYTECHNIC INSTITUTE · PI DORDICK, JONATHAN S., SCHAFFER, DAVID V · 2012 to 2015
$2.0M
NIEHS NIH HHS R01 ES020903
6 · The paper itself

Abstract

There is a critical need to generate functional hepatocytes to aid in liver repair and regeneration upon availability of a renewable, and potentially personalized, source of human hepatocytes (hHEP). Currently, the vast majority of primary hHEP are obtained from human tissue through cadavers. Recent advances in stem cell differentiation have opened up the possibility to obtain fully functional hepatocytes from embryonic or induced pluripotent stem cells, or adult stem cells. With respect to the latter, human bone marrow mesenchymal stromal cells (hBMSCs) can serve as a source of autogenetic and allogenic multipotent stem cells for liver repair and regeneration. A major aspect of hBMSC differentiation is the extracellular matrix (ECM) composition and, in particular, the role of glycosaminoglycans (GAGs) in the differentiation process. In this study, we examine the influence of four distinct culture conditions/protocols (T1-T4) on GAG composition and hepatic markers. α-Fetoprotein and hepatocyte nuclear factor-4α were expressed continually over 21 days of differentiation, as indicated by real time quantitative PCR analysis, while albumin (ALB) expression did not begin until day 21. Hepatocyte growth factor (HGF) appears to be more effective than activin A in promoting hepatic-like cells through the mesenchymal-epithelial transition, perhaps due to the former binding to the HGF receptor to form a unique complex that diversifies the biological functions of HGF. Of the four protocols tested, uniform hepatocyte-like morphological changes, ALB secretion, and glycogen storage were found to be highest with protocol T2, which involves both early- and late-stage combinations of growth factors. The total GAG profile of the hBMSC ECM is rich in heparan sulfate (HS) and hyaluronan, both of which fluctuate during differentiation. The GAG profile of primary hHEP showed an HS-rich ECM, and thus, it may be possible to guide hBMSC differentiation to more mature hepatocytes by controlling the GAG profile expressed by differentiating cells.

Indexed as

Cell DifferentiationActivinsalpha-FetoproteinsBone and BonesCells, CulturedCellular Reprogramming TechniquesGlycosaminoglycansHepatocyte Growth FactorHepatocyte Nuclear Factor 4HepatocytesHumansMesenchymal Stem Cellsactivin AActivinsalpha-FetoproteinsGlycosaminoglycansHepatocyte Growth FactorHepatocyte Nuclear Factor 4adult mesenchymal stromal cellschondroitin sulfatefunctional hepatocytesGAG temporal remodelingheparan sulfatehyaluronan

Identifiers

PMID30572803
PMCPMC6389772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.